ZA202004701B - Anti-b7-h4 antibody, antigen-binding fragment thereof and pharmaceutical use thereof - Google Patents
Anti-b7-h4 antibody, antigen-binding fragment thereof and pharmaceutical use thereofInfo
- Publication number
- ZA202004701B ZA202004701B ZA2020/04701A ZA202004701A ZA202004701B ZA 202004701 B ZA202004701 B ZA 202004701B ZA 2020/04701 A ZA2020/04701 A ZA 2020/04701A ZA 202004701 A ZA202004701 A ZA 202004701A ZA 202004701 B ZA202004701 B ZA 202004701B
- Authority
- ZA
- South Africa
- Prior art keywords
- antibody
- antigen
- binding fragment
- pharmaceutical use
- humanized
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810142118 | 2018-02-11 | ||
| PCT/CN2019/074397 WO2019154315A1 (zh) | 2018-02-11 | 2019-02-01 | 抗b7-h4抗体、其抗原结合片段及其医药用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA202004701B true ZA202004701B (en) | 2023-12-20 |
Family
ID=67548182
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2020/04701A ZA202004701B (en) | 2018-02-11 | 2020-07-29 | Anti-b7-h4 antibody, antigen-binding fragment thereof and pharmaceutical use thereof |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US11472882B2 (https=) |
| EP (1) | EP3753951A4 (https=) |
| JP (2) | JP7393337B2 (https=) |
| CN (2) | CN116693686A (https=) |
| AU (1) | AU2019218319B2 (https=) |
| BR (1) | BR112020015736A2 (https=) |
| CA (1) | CA3089246A1 (https=) |
| MX (1) | MX2020008181A (https=) |
| TW (1) | TWI823895B (https=) |
| WO (1) | WO2019154315A1 (https=) |
| ZA (1) | ZA202004701B (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3753951A4 (en) * | 2018-02-11 | 2022-03-16 | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. | ANTI-B7-H4 ANTIBODIES, ANTIGEN-BINDING FRAGMENT THEREOF AND PHARMACEUTICAL USE THEREOF |
| MX2021014960A (es) * | 2019-06-06 | 2022-03-04 | Shanghai Hansoh Biomedical Co Ltd | Conjugado de farmaco-anticuerpos anti-b7-h4 y uso medicinal del mismo. |
| CN115298220B (zh) * | 2020-03-24 | 2024-12-20 | 上海翰森生物医药科技有限公司 | 抗体-药物偶联物及其医药用途 |
| TW202144425A (zh) * | 2020-04-17 | 2021-12-01 | 大陸商上海翰森生物醫藥科技有限公司 | 特異性抗原結合分子，其製備方法及醫藥用途 |
| CA3183994A1 (en) | 2020-06-24 | 2021-12-30 | Philip James Dolan Iii | Antibodies recognizing sortilin |
| IL310780A (en) * | 2020-08-18 | 2024-04-01 | Abl Bio Inc | Anti-b7-h4/anti-4-1bb bispecific antibodies and use thereof |
| JP2024501894A (ja) | 2021-01-04 | 2024-01-16 | メルサナ セラピューティクス インコーポレイテッド | Ｂ７ｈ４ターゲティング抗体－薬物コンジュゲートおよびその使用方法 |
| MX2023011310A (es) | 2021-03-26 | 2023-10-05 | Innate Pharma | Anclajes de citocina para proteinas de celulas nk de union a nkp46. |
| BR112023025331A2 (pt) | 2021-06-09 | 2024-02-27 | Innate Pharma | Proteína multiespecífica, composição farmacêutica, célula recombinante, ácido nucleico ou conjunto de ácidos nucleicos, uso de uma proteína ou composição, métodos ou uso |
| WO2022258691A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a |
| WO2022258678A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a |
| US20240309095A1 (en) * | 2021-07-07 | 2024-09-19 | Incyte Corporation | Anti-b7-h4 antibodies and uses thereof |
| AR127806A1 (es) * | 2021-12-01 | 2024-02-28 | Kadmon Corp Llc | Anticuerpos b7-h4 y proteínas de fusión de anticuerpo b7-h4 / il-15 |
| JP2025500457A (ja) * | 2021-12-23 | 2025-01-09 | プロシーナ バイオサイエンシーズ リミテッド | ソルチリンを認識する抗体 |
| CA3245849A1 (en) * | 2022-03-30 | 2025-02-03 | Duality Biologics (Suzhou) Co., Ltd. | ANTIBODY-DRUG CONJUGATE B7H4 AND ITS USE |
| WO2024208818A1 (en) | 2023-04-04 | 2024-10-10 | Innate Pharma | Modular chimeric antigen receptor |
| WO2024213081A1 (zh) | 2023-04-12 | 2024-10-17 | 上海翰森生物医药科技有限公司 | 抗体药物偶联物在制备预防和/或治疗癌症的药物中的用途 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030091580A1 (en) * | 2001-06-18 | 2003-05-15 | Mitcham Jennifer L. | Compositions and methods for the therapy and diagnosis of ovarian cancer |
| US6858710B2 (en) * | 1998-12-17 | 2005-02-22 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of ovarian cancer |
| EP3058955B1 (en) * | 2005-03-24 | 2019-05-29 | Millennium Pharmaceuticals, Inc. | Antibodies that bind ov064 and methods of use therefor |
| US8759490B2 (en) * | 2005-03-24 | 2014-06-24 | Millennium Pharamaceuticals, Inc. | Antibodies that bind OV064 and methods of use therefor |
| CN102875681A (zh) * | 2005-07-08 | 2013-01-16 | 拜奥根Idec马萨诸塞公司 | 抗-αvβ6抗体及其用途 |
| EA201000910A1 (ru) | 2007-11-30 | 2011-04-29 | Бристоль-Мейерз Сквибб Компани | Конъюгат "моноклональное антитело против в7н4/лекарственное средство" и способы его применения |
| PT3042917T (pt) * | 2010-08-12 | 2018-05-02 | Lilly Co Eli | Anticorpos do péptido beta amilóide anti-n3pglu e seus usos |
| JP6120848B2 (ja) * | 2011-08-15 | 2017-04-26 | メディミューン，エルエルシー | 抗ｂ７−ｈ４抗体およびその使用 |
| WO2013157105A1 (ja) * | 2012-04-18 | 2013-10-24 | 公立大学法人大阪市立大学 | ムチンサブタイプ５ａｃ特異的ヒト化抗体およびその利用 |
| AU2013361275B2 (en) * | 2012-12-19 | 2016-11-24 | Amplimmune, Inc. | Anti-human B7-H4 antibodies and their uses |
| AU2014244424A1 (en) * | 2013-03-14 | 2015-08-27 | Genentech, Inc. | Anti-B7-H4 antibodies and immunoconjugates |
| US9562099B2 (en) | 2013-03-14 | 2017-02-07 | Genentech, Inc. | Anti-B7-H4 antibodies and immunoconjugates |
| CN103981150B (zh) * | 2014-03-28 | 2016-06-01 | 苏州大学 | 抗人b7-h4单克隆抗体及其制备和应用 |
| JP6943760B2 (ja) * | 2014-09-12 | 2021-10-06 | ジェネンテック， インコーポレイテッド | 抗ｂ７−ｈ４抗体及び免疫複合体 |
| WO2016160620A2 (en) * | 2015-03-27 | 2016-10-06 | University Of Southern California | Car t-cells for the treatment of b7-h4 expressing solid tumors |
| WO2018021301A1 (ja) * | 2016-07-26 | 2018-02-01 | 静岡県 | 抗ｂ７－ｈ４抗体 |
| CN107299085B (zh) * | 2017-05-26 | 2020-09-29 | 广东医科大学 | 分泌抗人b7-h4胞外单克隆抗体杂交瘤细胞株和抗人b7-h4单克隆抗体及其应用 |
| EP3753951A4 (en) * | 2018-02-11 | 2022-03-16 | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. | ANTI-B7-H4 ANTIBODIES, ANTIGEN-BINDING FRAGMENT THEREOF AND PHARMACEUTICAL USE THEREOF |
| MA52416A (fr) * | 2018-03-02 | 2021-04-21 | Five Prime Therapeutics Inc | Anticorps b7-h4 et leurs procédés d'utilisation |
| KR102227515B1 (ko) | 2018-12-18 | 2021-03-12 | 주식회사 포스코 | 제올라이트 및 그 제조방법 |
-
2019
- 2019-02-01 EP EP19750949.0A patent/EP3753951A4/en active Pending
- 2019-02-01 JP JP2020542138A patent/JP7393337B2/ja active Active
- 2019-02-01 WO PCT/CN2019/074397 patent/WO2019154315A1/zh not_active Ceased
- 2019-02-01 CN CN202310820681.5A patent/CN116693686A/zh active Pending
- 2019-02-01 CN CN201980001361.9A patent/CN110366560B/zh active Active
- 2019-02-01 BR BR112020015736-8A patent/BR112020015736A2/pt unknown
- 2019-02-01 AU AU2019218319A patent/AU2019218319B2/en active Active
- 2019-02-01 US US16/967,016 patent/US11472882B2/en active Active
- 2019-02-01 MX MX2020008181A patent/MX2020008181A/es unknown
- 2019-02-01 CA CA3089246A patent/CA3089246A1/en active Pending
- 2019-02-11 TW TW108104453A patent/TWI823895B/zh active
-
2020
- 2020-07-29 ZA ZA2020/04701A patent/ZA202004701B/en unknown
-
2023
- 2023-11-21 JP JP2023197481A patent/JP2024026132A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112020015736A2 (pt) | 2020-12-08 |
| AU2019218319B2 (en) | 2025-11-13 |
| JP2024026132A (ja) | 2024-02-28 |
| US11472882B2 (en) | 2022-10-18 |
| US20210032347A1 (en) | 2021-02-04 |
| TWI823895B (zh) | 2023-12-01 |
| AU2019218319A1 (en) | 2020-08-13 |
| CN116693686A (zh) | 2023-09-05 |
| TW201934581A (zh) | 2019-09-01 |
| KR20200119846A (ko) | 2020-10-20 |
| JP7393337B2 (ja) | 2023-12-06 |
| EP3753951A1 (en) | 2020-12-23 |
| CN110366560B (zh) | 2023-07-28 |
| CA3089246A1 (en) | 2019-08-15 |
| JP2021513331A (ja) | 2021-05-27 |
| MX2020008181A (es) | 2020-09-18 |
| CN110366560A (zh) | 2019-10-22 |
| WO2019154315A1 (zh) | 2019-08-15 |
| EP3753951A4 (en) | 2022-03-16 |
| RU2020124155A (ru) | 2022-03-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202004701B (en) | Anti-b7-h4 antibody, antigen-binding fragment thereof and pharmaceutical use thereof | |
| MX2021005396A (es) | Anticuerpo anti-cd73, fragmento de union a antigeno y aplicacion del mismo. | |
| MY208022A (en) | Anti-claudin 18.2 antibody and application thereof | |
| PH12016501120A1 (en) | Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof | |
| MX2020007406A (es) | Anticuerpo pd-l1, fragmento de union al antigeno del mismo y uso farmaceutico del mismo. | |
| MX2018015393A (es) | Anticuerpo lag-3, fragmento de union al antigeno del mismo y aplicacion farmaceutica del mismo. | |
| PH12018550179A1 (en) | Anti-pd-1 antibodies, method for producing same and method for using same | |
| MX2019014375A (es) | Anticuerpo anti-cd40, fragmento de union a antigeno del mismo, y uso medico del mismo. | |
| MX2020002750A (es) | Anticuerpo il-6r y fragmento de union a antigeno y uso medico. | |
| MY209791A (en) | Anti-cd79b antibody, antigen-binding fragment thereof, and pharmaceutical use thereof | |
| MX2021008888A (es) | Anticuerpos anti-tau humanizados. | |
| MX2021003168A (es) | Anticuerpo anti-ox40, fragmento de union al antigeno del mismo y uso farmaceutico. | |
| PH12016501366A1 (en) | Novel anti-baff antibodies | |
| EP4631978A3 (en) | Humanized or chimeric cd3 antibodies | |
| NZ630610A (en) | Tau peptides, anti-tau antibodies, and methods of use thereof | |
| MX2021009041A (es) | Anticuerpo anti-pd-1, fragmento de union a antigeno del mismo y uso farmaceutico del mismo. | |
| ZA202201946B (en) | Anti-bcma antibody, antigen-binding fragment thereof and medical use thereof | |
| MX2019015914A (es) | Anticuerpos quiméricos para el tratamiento de enfermedades por deposición de amiloide. | |
| MX2018009264A (es) | Anticuerpo de trombina, fragmento de antigeno y sus usos farmaceuticos. | |
| MX2020010119A (es) | Anticuerpo anti-cd27, fragmento de union a antigeno del mismo y uso medico del mismo. | |
| MX2021002531A (es) | Anticuerpo anti-cd38, fragmento de union al antigeno y uso farmaceutico. | |
| MX2021004226A (es) | Terapia combinada contra el cáncer. | |
| MX2021010116A (es) | Anticuerpo anti-pd-l1 y uso de este. | |
| MY201928A (en) | Il-5 antibody, antigen binding fragment thereof, and medical application therefor | |
| MX2020008730A (es) | Regímenes de dosificación de anticuerpo b7-h4. |